We are gratified the FDA has granted Orphan Drug Designation to daraxonrasib for the treatment of pancreatic cancer, a devastating disease with limited therapeutic options and representing a large ...

Two companion studies published in Cancer Research by scientists at Moffitt Cancer Center identify distinct but complementary ...

The RAS family commonly drives the growth and survival of human cancers. Mutations in KRAS, NRAS, and HRAS occur in approximately 20% of all human cancers, including solid tumors, such as pancreatic, ...

RBC Capital calls Revolution Medicines (RVMD) a top cancer drug stock, citing strong efficacy and huge growth potential for its lead candidate, daraxonrasib. Read more here.

Daraxonrasib received FDA orphan drug designation for pancreatic cancer, targeting RAS mutations in pancreatic ductal ...

Revolution Medicines, Inc. ( RVMD) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 11, 2025 9:00 AM EST All right. So we'll get started right away. So I'd like to welcome ...

Detailed price information for Tango Therapeutics Inc (TNGX-Q) from The Globe and Mail including charting and trades.

The highest prevalent prescription rates were observed in thyroid (10.1%), breast (7.2%), and endometrial (7.1%) cancers, ...

Two companion studies published in Cancer Research from scientists at Moffitt Cancer Center identify distinct but complementary approaches to overcoming drug resistance in KRAS G12C–mutant non-small ...

A comprehensive review in The Journal of Clinical Investigation finds no overall link between GLP-1 receptor agonists and ...